natgillin/translations-raw huggingface dataset:
SCA's aktiviteter inden for hygiejne- og tissue-produkter udøves af virksomhedens datterselskab, SCA Mölnlycke.
SCA's activities in the area of hygiene products and tissue products are carried out within its subsidiary, SCAMölnlycke.
PWA fremstiller en række papir- og emballageprodukter, især fint papir med eller uden overfladebehandling, tissueprodukter, transportemballage, emballagepap og specialpapir. Efter transaktionen vil den nye koncern være den største leverandør inden for den europæiske papirindustri (med en omsætning på ca. 5 700 mio. ECU på verdensplan).
PWA is a manufachuerof a range of paper and packaginsploducts, in particular coarcdand uncoafedfine paper, tiszue products, transport paokaging container board and speciality papers.Following the operation"the new group (worldwide turnover about ECU 5,700 million) will be thelargest supplier in the Europea.n paper indushy.
SCA og PWA er begge aktive på flere produktmarkeder med bl.a. levering af tissueprodukter, transportemballage og træfrit papir uden overfladebehandling.
SCA and PWA are both active in several produot markets involving the supply of tissue products,transport packaging and uncoatedwood-free papers.
PWA udøver dog ikke virksomhed på flere af de hovedområder, hvor SCA opererer.
Howwer, PWA is not active in a number of theprincipal areas in which SCA is involved.
Selv om SCA og PWA er betydelige virksomheder på nogle af de berørte markeder for tissueprodukter, hvor den nye virksomhed ville få betydelige markedsandele både inden for EØS som helhed og i de enkelte medlemsstater, mente Kommissionen, at virksomheden ville komme til at konkurrere med andre multinationale producenter af tissue-produkter.
The Commission consid€r€dthat although SCA and PWA are important operators in certain atrect€dtissue product markets where lhe newentity would have substantial market shar€s both within the EEAas a whole and within individual Member States, it would continue to face competition from othermultinational tissueproducl manufacturers.In particular, the Commission took into aocountthat in thespecific tissue product markets affected by the operation (i.e. non-feminine protection products), whichare ofa less sophisticaled naturp and.for which recognisd brands are less relevant than thoseconsiderpd in the rpcpnt Procter & Gamble/VP Schickedanz(II) case market entry barriers arecomparatively weak. This is demonsbatedby the relatively high penetration of private label productsand the r€latively high price sensitivity of consumers. Wiürin the other affected markets (transport packaging and uncoatedwood-free papers),it was foundthat the combined share of SCA and PWA in EEA-wide markets did not give rise to competitionconcerng as in all these markets there werr large andfinancially sfong companies to whom customerscould turn.
Kommissionen godkendte et joint venture, hvorved Noranda Forest Inc og Glunz AG samlede deres henholdsvis europæiske og britiske aktiviteter vedrørende træbaserede plader i selskabet Norbord Holdings Ltd (for øjeblikket et datterselskab af Noranda, der efter transaktionen skulle omdøbes til CSC Forest Products Ltd).
RULES IN THE EUROPEAN UNION would be combined in Noöord Holdings Ltd (cunently a Noranda subsidiary to be renarned CSCForcst hoducts Ltd following consummationof the transaction).
Efter transaktionen vil Noranda Forest Inc, der er en canadisk træforarbejdningsvirksomhed, trække sig ud af det europæiske marked for plader.
Upon completion of the operation Noranda Forrst Inc, a Canadian forest products company, was towithdraw from the European panel board market.
Det eneste produkt, som transaktionen vil medføre en betydelig kombineret markedsandel for, er "oriented strand board" (OSB), der er et forholdsvis nyt produkt i Europa, og for hvilket Glunz og Norbord Holdings Ltd har de eneste to nuværende produktionslinjer i EU.
The only panel board p,roductfor which theoperation will lead to a substantial combined market share is oriented stand board (OSB), acomparatively new product in Europe, for whioh Glunz andNoöond Holdings Ltd have the only twolines cunently producing in the European Union,
Det samlede forbrug af OSB er meget beskedent sammenholdt med forbruget af andre plader, især træfiberplade og krydsfiner, som OSB erstatter til visse formål.
Total consumption of OSB is very small compared to that of other panel board products, notablyparticle boad and plywood, for which OSB is a substitutc in certain applications.
Glunz' og Norbords markedsandele inden for såvel OSB og træfiberplade som OSB og krydsfiner gav heller ikke anledning til betænkeligheder med hensyn til konkurrencen.
Furthermore, themarket shares of Glunz and Noöord on markets combining OSB andpaiticle board, and for OSB andplywood respectively, do not give rise to any competition concems.
Desuden er mindst én anden større producent af plader ved at installere et OSB-anlæg i EU.
In additioq at least one othermajor producer of panel board products is installing an OSB line in the European Union.
Repola og Kymmene var store finske selskaber, der udøvede international virksomhed inden for trykpapir og emballagematerialer.
Repola and Kymmene were large Finnish companies active internationallyin the fields ofprinting pap€r and packaging materials.
Transaktionen omfattede produktmarkederne for papir til aviser og blade samt papirsække.
The operation involved product markets fornewsprint magazine paper and papersacks. sacks.
Markedet for papir til aviser og blade omfatter mindst Vesteuropa, og i lighed med alle andre større europæiske papirproducenter markedsfører og sælger Repola/Kymmene deres produkter i næsten alle medlemsstater.
The markets for newsprint and magazine paper ar€ at least Western European in scope and Repola/Kymmene, like all other major European paper poducers, market and distribute their products in almost all Member States.
Det nye selskab vil bljve Europas største inden for papir til aviser og blade.
The new company will be the largest European player in newsprint andmagazine paper.
Dets samlede markedsandel overstiger dog ikke 20% på hvert af disse to markeder, og flere af dets konkurrenter indtager en stærk markedsstilling.
However, its combined market share does not exoeed 20Vo in either of these fio markets and several of their competitors have stong positions.
Sammen med fem andre finske papirproducenter var Repola medlem af Finnpap Marketing Association, der var en fælles salgsorganisation, som markedsfører medlemmernes papirprodukter på verdensplan.
Repola was, together with five other Finnish paper pnrducers, a mernber of Finnpap Marketing Association.
Kymmene, der ikke er medlem af Finnpap, har sit eget salgsnet.
Finnpap was a joint sales organisation which markets the paper products of its memberson a worldwide basis.Kymmene, which is not a member of Finnpap, has its own sales network.
I deres anmeldelse havde parterne ikke gjort klart, om markedsføring og salg af papir produceret af Repola ville forblive i Finnpap eller om alle det nye selskabs papirprodukter ville blive markedsført gennem Kymmenes eget distributionsnetværk.
Inthe notification the parties had not made clear their plans as to whether the marketing of paperpoduced by Repola would remain in Finnpap or whether all the paper products of the new companywould be marketed through Kymmene's own distribution networt.
Hvis Repola var fortsat med at distribuere dets produkter gennem Finnpaps netværk, ville det have skabt en strukturel forbindelse mellem Kymmenes markedsdsføring af papir og de øvrige producenter repræsenteret ved Finnpap.
If Repola had continued todistribute its productsürough Finnpap'snetworlq a link betrveen Kymmene's paper marketing and theother prcducers representedby Finnpap would have emerged.In such a situation the scope of themerger would have beenortended to include the combined sales of the new company together withthe other Finnish producers selling through Finnpap.
I denne situation ville effekten af fusionen have inkluderet det samlede salg for det nye selskab samt salget for de øvrige finske producenter, der sælger
Given this background,in order to eliminate anypossible concerns about the role of Finnpap, the parties decided to commit themselves not to sell paperproducts through the Finnpap joint sales agency.
På baggrund af Repolas og Kymmenes tilsagn konkluderede Kommissionen, at fusionen ikke ville skabe eller styrke en dominerende stilling.
In light of the commitnents given by Repola and Kymmene,the Commission has concluded that theconcentration does not srpateor shengthena dominant position.
Olieprodukter, kemiske produkter, plast osv.
Petroleum Products, Chemicals, Plestics Etc
Joint venture-selskabet skulle overtage alle moderselskabernes aktiver i de pågældende to lande, dvs. terminaler, depoter, lastvogne og servicestationer.
The joint venture would take overall the assets of the mother companies in the two countries concerned that is, terminals, depots, trucksand service stations.
Denne transaktion faldt ind under fusionsforordningen, da der var tale om et selvstændigt joint venture med de faciliteter, der er nødvendige for at udøve alle en virksomheds normale funktioner på et bestemt marked.
This operation fell under the jurisdiction of the Merger Regulation, as the joint venture had thecharacrcristics of an autonomousjoint ventue which is active in a trade market with the necessaryfacilities to perform the normal functions of a tading company in such a market.
I betragtning af at joint venture-selskabet ikke ville være moderselskabernes største kunde, at moderselskabernes aktiviteter varierede betydeligt, og at moderselskaberne kun i begrænset omfang var til stede på markedet for levering af raffinerede olieprodukter til forhandlerne (tilsammen 9%), mente Kommissionen ikke, at de ville få mulighed for at foretage en indbyrdes samordning på dette marked.
Taking into accountthe fact that the W would not be the main customer of each of the par€nts,the very different natureof the two parents'activities and their limited presenceon the upstream market for supply of refinedoil products to distributors (9% together), the Commission found that there would be no scope forcoordination between them on this upstream market.
Kommissionen godkendte et joint venture mellem Enichem og Union Carbide (UCC) på markedet for Polyethylen (PE), der er et termoplastmateriale, som anvendes til fremstilling af en lang række forskellige slutprodukter, herunder film og formartikler.
The Commission authorised a joint venture between Enichern and Union Carbide(UCC) in the marketfor polyethylene ("PE'), a thermoplastic used for the manufacture of a variety of end-productsincluding film and moulded goods.
Kommissionen undersøgte den planlagte fusions virkninger på tre særskilte markeder, nemlig markedet for produktion og salg af PE-harpiks, markedet for ethylenleverancer (der er det råmateriale, som anvendes i PE-produktion) og markedet for PE-teknologilicenser.
The Commhsion qramined the effects of the proposed operation on three separate markets: the marketfor the production and sale of PE resins;the upstneam market for the supply of ethylene (which is theraw material used in the production of PE); and the market for PE technology licensing market.
Kommissionen konkluderede, at fusionen ikke ville skabe eller styrke en dominerende stilling på nogen af disse markeder.
The Commission concluded that the op€ration would not create or stengthen a dominant position in anyof these markets.
På markedet for produktion af PE-harpiks findes der tre hovedtyper af PE-harpiks defineret på grundlag af deres massefylde og krystaliseringsgrad, nemlig HDPE (High-Density), LDPE (Low-
In the market for the production of PE resins, therc are three basic families of PE resins defined onthe basis of their degree of density and crystatlinity, namely High'Density (HDPE), Low-Density
Der er en stigende efterspørgsel efter PE-harpiks, specielt LLDPE, der er ved at afløse LDPE, og HDPE, der har andre karakteristika og anvendelsesformål (større styrke, men lavere bearbejdelighed).
There is a growing demand for PE resins, especially for LLDPE, which is gradually replacing LDPE, and for HDPE, which has different characteristics andend-uses (greater st€ngth but lower prooessability).
I Vesteuropa findes der en række større producenter af PE-harpiks, bl.a. Enichem, Borealis, BP, Dow, DSM og Exxon.
ln Westem Eunrpethere ur" a nurnb", of major producers of PE resins, including Enichem, Borealis,BP, Dow, DSM and Exxon.
Selv om Enichem er en af de største leverandører af PE-harpiks, var dens andel af PE-harpiks ikke på over 25%, hverken betragtet som helhed eller inden for de enkelte PE-typer. UCC øgede kun i ganske ringe omfang denne markedsandel gennem sin deltagelse i et nyt joint venture med Elf Atochem.
Although Enichem is one of the largest suppliers of PE resins, its sharcof PE resins either as whole or within each PE family did not exceed25%.UCC did not add to thismarket share, except to a very small exten! through its participation in a recentjoint venture with Elf Atochem.
Desuden tilhører flere af joint ventureselskabets konkurrenter store vertikalt integrerede koncerner, der har deres egen PE-teknologi.
Furthermore, several of the W's competitors belong to large, vertically integrated groupsthat have their own PE technology.
På markedet for ethylenproduktion var Enichem den eneste producent og hovedleverandør af dette råmateriale i Italien. Importen til Italien er meget beskeden i betragtning af transportproblemerne og behovet for havne- og oplagringsfaciliteter.
ln the upstream market for the production of ethylene, Enichem was the only producer and mainsupplier of this raw material in Italy; imports into Italy are very small in view of transportationdifficulties and the need for port and storage facilities.
Joint venture-selskabet styrkede dog ikke denne eksisterende markedsstilling, idet UCC ikke producerede ethylen i Vesteuropa. Desuden ville Enichems regionale styrke ikke kunne medføre dominans på PE-markedet, fordi Italien kun tegner sig for en lille andel af den samlede ethylenkapacitet i Vesteuropa.
However, the joint venture did not strengthenthis pre-existing market positiog since UCC was not a producer of ethylene in Westem Europe,Moreover, Enichem's r€gional shength was not likely to lead to a creation of dominance on thedownstream market for PE, be c a us J ltaly only accounts for a small proportion of total Western European ethylene capacity.
Da efterspørgslen efter HDPE og LLDPE forventes at blive større end efter LDPE, vil potentielle licenstagere til PE-teknologien naturligvis søge at opnå licenser på lavtryksprocesserne (gasfase, opslæmning eller opløsning), der kan producere det ene af produkterne eller dem begge.
As thedemand for HDPE and LLDPE is expected to be stronger than LDPE, potential licenseesfor PEtechnology will naturally seek licences for low-pressureprocesses (gas-phase,slurry or solution) thatproduce one or both of these products.
I denne forbindelse finder i hvert fald nogle potentielle licenstagere i Vesteuropa det vigtigt, at man med en bestemt teknologi kan skifte fra produktion af HDPE til produktion af LLDPE i et enkelt anlæg.
In this context, the capability of a technology to switch production from HDPE to LLDPE at a single plant (that is, a "swing" plant) is also important for atleast some potential licenseesin Westem European.
Kommissionen konkluderede dog, at oprettelsen af Polimeri Europa ikke ville forbedre Unipols stilling inden for PE-teknologi væsentligt, idet Enichems teknologiske erfaringer hovedsagelig er begrænset til højtryksteknologi og kun i begrænset omfang vedrører gasfase eller opslæmning.
However, the Commissionconcludedthat the creation of Polimeri Europa would not sigrificantly improve Unipol's position in
Kommissionen undersøgte også joint ventureselskabets virkninger på leverancerne af propylen, der er et af biprodukterne ved ethylenproduktionen. Den konkluderede, at fusionen heller ikke ville forøge markedsandelene på dette område.
PE technology, since Enichem's technological experience is mainly confined to the area of high-prcssure tec hn ol og S r and only to a very limited extent in gas-phaseor slurry.
Sammen med det anmeldte joint venture forelagde parterne også Kommissionen en aftale mellem Enichem og joint venture-selskabet om levering af ethylen.
The Commission also examined the effects of the joint venture on the supply of propylene,one of theby-products ofthe ethylene production process.
Ved vurderingen af denne aftale tog Kommissionen hensyn til tredjemands interesser i, at der var tilstrækkelige mængder ethylen til rådighed i området.
It concluded that the operation would not lead to anaddition ofmarket shares in that areaeither. either.
Kommissionen godkendte, at det saudiarabiske olieselskab, Saudi Aramco, og Vardinoyannis-familien oprettede et joint venture ved, at Saudi Aramco erhvervede 50% i to eksisterende græske selskaber, Motor Oil Corinth Refineries S.A.
The parties also submitted to the Commission, in conjunction with the notified joint venture, anethylene supply agreement between Enichem and the joint venture.
(MOH), der er et olieraffinaderi, og Avinoil Industrial and Maritime
In assessing this agreement the Commission took into account the interests of third parties in order to assurethem of the availabilityof suffrcient quantities of ethylene in the area.
(Avin), der er detailhandler af raffinerede olieprodukter.
('Avinn), a retailer of refinedpeholeum products.
Før fusionen havde Vardinoyannis-familien enekontrollen med disse to selskaber.
Before the operation these two companies were exclusively controlled by the Vardinoyannis family.
Saudi Aramco, der ejes 100% af Kongeriget Saudi Arabien, beskæftiger sig med olieeftersøgning, -produktion, -transport, -raffinering og -salg, men hovedsagelig uden for Europa.
Saudi Aramco, a oompany wholly ovrned by the Kingdom of Saudi Arabi4 is engaged in theexploration, production, transport, refinins and marketing of oil primarily outside Europe.
Medlemmerne af Vardinoyannis-familien er græske statsborgere med mange forretningsaktiviteter, herunder olieprodukter, skibsfart, bankvirksomhed, ejendomsvirksomhed, mediesektoren, hotelvirksomhed og rekreative aktiviteter.
Themembers of the Vardinoyannis family are Greek nationals with multiple business activities includingoil and petroleum produots,shipping banking, real estate,medi4 hotels and leisure.
Fusionen ville hovedsagelig påvirke de græske markeder for raffinering og detailsalg af raffinerede olieprodukter. Da Saudi Aramco ikke var til stede på disse markeder i Grækenland før fusionen, medførte denne ingen forøgelse af markedsandelene.
The concentration would maihly affect the Greek markets for the refming and the retail distibutionof refined petroleum products.
Den 30. januar 1995 anmeldte Glaxo plc (Glaxo) sit offentlige overtagelsestilbud Wellcome plc (Wellcome).
On 30 January 1995 Glaxo plc ("Gla:ro") notifred to the Commission is public bid for the acquisitionof Wellcome plc ("Wellcome").
Glaxos og Wellcomes aktiviteter på markedet for medicinalvarer supplerede stort set hinanden.
The activities of Glaxo and Wellcome in the pharmaceutical marketwere basically complementary.
Desuden mente Kommissionen, at selskaberne var udsat for konkurrence fra andre store medicinalfirmaer på de fleste af de markeder, hvor de var til stede.
Furthermore, the Commission found that the companies are subjectto competitive pressuresexerted by other large pharmaceutical companies in most of the marketswhere they ar€ pr€sent.
Kommissionen undersøgte dog specielt spørgsmålet om, hvorvidt overtagelsen af Wellcome kunne styrke Glaxos stærke stilling væsentligt på et bestemt område, nemlig migrænebehandling.
However, the Commission specifically addressedthe issue of whether the acquisition of Wellcomecould significantly bolster Gla: < o'sstong position in one particular therapy area, that is, migrainetherapy.
Glaxo havde en stærk stilling inden for behandling af migræne med sit produkt Imigran, og var også langt fremme med udvikling af et andet produkt på dette område.
Glaxo had a strong position in the tneaünentof migraines with its product "Imigran", and italso had a compound in an advanced stage of development in this therapeutic area.
Samtidig markedsførte Wellcome kun én form for migrænemedicin, der ikke var patentbeskyttet, og afsætningen og markedsandelen i forbindelse med dette produkt var ringe i alle EU-lande. Wellcome var dog i gang med at udvikle et produkt, der ville kunne konkurrere med Glaxos Imigran i den nærmeste fremtid. Fusionen ville derfor betyde, at Glaxo samtidig med sin store markedsandel i flere medlemsstater blev ejer af to produkter under udvikling.
At the same time,Wellcome crirrently marketed only one off-patent medicine used in the anti-migraine areq and thisproduct had only limited sales and market share in all EU Mernber States.
For at fjerne al mulig tvivl om, hvorvidt overtagelsen af Wellcome var forenelig med fællesmarkedet, forpligtede Glaxo sig til at meddele licens til tredjemand på et af de to vigtige produkter under udvikling.
In order to remove any possible doubts as to the compatibility of its acquisition of Wellcome with thecommon market, Glaxo urrdertook to grant a licence of one of these two main anti-migrainecompounds under development to a third party.
Under alle omstændigheder konstaterede Kommissionen, at flere andre medicinalfirmaer også var i gang med at udvikle nye produkter til behandling af migræne svarende til Wellcomes og Glaxos, og at i hvert fald nogle af disse produkter ville komme på markedet på nogenlunde samme tidspunkt. Da flere af disse konkurrerende virksomheder også var større medicinalfirmaer, der kunne sælge deres produkter på verdensplan, konkluderede Kommissionen, at det kun havde begrænset virkning, at Wellcome ikke længere ville være konkurrent på dette område.
In anyeven! the Commission found that several other pharmaceutical firms were also in the process of developing new anti-migraine compounds similar tothose of Wellcome's and Gloro's, with at least some of these products due to come onto the market in a similar time frame.
ANVENDELSEN AF KONKURRENCEREGLERNE I DEN EUROPÆISKE UNION
Both companies wereactive in rrsearph for new compounds for the teatnent of HIV/AIDS.
Europa-Kommissionen godkendte oprettelse af et joint venture mellem Behringwerke AG (Behringwerke)og Armour Pharmaceutical Co (Armour), hvor de to parter overførte deres respektive verdensomspændende virksomhed vedrørende plasmaderivatertiljoint venture-selskabet.
The European Commission approved the creation of a joint ventur€ between Behringwerke AG(Behringwerke) and Armour Pharmaceutical Co (Armour), where both parties hansfered theirrespective worldwide plasmaderivative businesses into the joint ventur€.
Behringwerke, der er datterselskab af Hoechst AG, og Armour, der indirekte tilhører Rhône-Poulenc, fremstiller begge medicinalvarer.
Behringwerke, a subsidiaryof Hoechst AG, and Armour, which indirectly belongsto Rhöne-Poulenc,are both manufacturers of pharmaceutical products.
Fusionen vedrørte en række plasmaderivater, hvor partemes aktiviteter overlappede hinanden i fire tilfælde, nemlig inden for humant albumin, intravenøst Immunglobulin, faktor VIII og faktor LX. Markederne for disse produkter er stadig nationale på grund af forskelle i de nationale registreringssystemer, sikkerhedsnormer og socialsikringsrefusion. I de fleste EØS-lande var parternes samlede markedsandele beskedne.
The concenhation concerned a variety of plasma-derived products, with the activities of the partiesovorlapping in four of these - humanalbumin, inhavenousimmunoglobulin, factor VIII and factor IX.Differing national systems for registration, safety standards and social security reimbursement havethe effect that the markets for these products are still national.
Men mens deres samlede markedsandel for faktor VIII var på ca. 30% i EØS, oversteg den 40% i Tyskland, mens den var betydelig højere i Østrig.
But whilst their combined shares for factor VIII in the EEA wasabout 30 per cent, in Germany it exceeded40 per cent and in Ausria it was sigrrificantly higher.